HiFiBiO partners with Pharmsynthez and IBCh to develop and commercialise SARS-CoV-2 neutralising antibody in Russia

This article was originally published here

The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19, through clinical development and commercial sale in Russia, pending approval from the Ministry

The post HiFiBiO partners with Pharmsynthez and IBCh to develop and commercialise SARS-CoV-2 neutralising antibody in Russia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply